The spontaneously hypertensive rat (SHR) is a genetically hypertensive rat model used to study human essential Abstract-Imatinib mesylate is a specific tyrosine kinase inhibitor that may block the platelet-derived growth factor and transforming growth factor pathways. These pathways are known to provoke fibroblast activation. We evaluated whether imatinib, by inhibiting these pathways, prevents diastolic dysfunction and attenuates myocardial remodeling using spontaneously hypertensive rats (SHRs). Eight-week-old male SHRs were randomly assigned to either imatinib treatment group (30 mg/kg per day; n=10; SHR-I) or hypertensive control group (distilled water, n=10; SHR-C). Wistar-Kyoto rats were used as normal controls (n=10). At 16 weeks, all rats underwent hemodynamic studies and Doppler echocardiography and then were euthanized. Their hearts were extracted for histopathologic, immunoblotting, and quantitative reverse transcriptase polymerase chain reaction analyses. Although imatinib did not affect blood pressure, it markedly reduced perivascular and interstitial fibrosis in the hearts of SHR. Echocardiogram showed that imatinib significantly reduced the left ventricular wall thickness (septal/posterior wall; SHR-C versus SHR-I, 18±1/19±2 versus 15±1/15±1 mm; P<0.001) and increased the E/A ratio (SHR-C versus SHR-I, 1.59±0.11 versus 1.84±0.16; P=0.001). Also, imatinib significantly reduced the mRNA expression of collagen type I, III, and platelet-derived growth factor receptor-β phosphorylation in the hearts of SHR. In addition, imatinib reduced collagen production by inhibiting the phosphorylation of c-abl and platelet-derived growth factor receptor-β in rat cardiac fibroblasts. In conclusion, these results suggest that imatinib could attenuate myocardial remodeling and improve left ventricular diastolic dysfunction in a hypertensive rat model by affecting platelet-derived growth factor and transforming growth factor-β1 pathway without the blood pressure-lowering 
H ypertension is a major risk factor for left ventricular (LV) hypertrophy and heart failure. Chronic hypertension leads to LV hypertrophy, which enables the heart to maintain a normal stroke volume, despite the increase in afterload. However, the heart undergoes pathological changes, which resulted in ventricular failure. The hallmark of pathological LV hypertrophy is reactive myocardial fibrosis, a progressive increase in the collagen content of the heart, which also plays an important role in heart failure. 1 Although molecules responsible for myocardial fibrosis have not been clearly elucidated, angiotensin II, aldosterone, and cytokines, including transforming growth factor-β (TGF-β), 2 interleukin-1, 3 tumor necrosis factor-α, 4 and platelet-derived growth factor (PDGF), 5 are known to provoke fibroblast activation within the connective tissue. These molecules are potential targets for downregulation of fibroblast activation. Indeed, the use of angiotensin-converting enzyme inhibitors, β-blockers, and aldosterone receptor antagonists has been associated with a decrease in myocardial fibrosis in experimental heart failure models. 6 PDGF stimulates fibroblasts to contract collagen matrices and differentiate into myofibroblasts. 7, 8 PDGF comprises a family of homo-or heterodimeric growth factors, including PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD. These isoforms act via 2 receptor tyrosine kinases: PDGF receptors-α (PDGFR-α) and β (PDGFR-β). 9 Imatinib mesylate inhibits not only BCR/ABL-mediated phophorylation but also other tyrosine kinase, such as c-abl, c-kit, and PDGFR.
hypertension. The SHR develops hypertension at 2 to 6 weeks, followed by progressive myocardial fibrosis, cardiac hypertrophy, and eventually heart failure. 11, 12 The purpose of this study was to evaluate whether imatinib prevents cardiac fibrosis and LV hypertrophy and thus improves LV diastolic dysfunction in SHR. Furthermore, we investigated whether imatinib mediates inhibition of PDGFR-β or c-abl tyrosine kinase activity in the aspect of attenuating myocardial remodeling.
Methods

Animal Preparation
This investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996). All procedures were performed in accordance with the protocols approved by the Institutional Animal Care and Use Committee in the School of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Eight-week-old male SHR and nonhypertensive Wistar-Kyoto (WKY) control rats were purchased via the Central Animal Laboratory at our institution. Study subjects were divided into normal controls (WKY; n=10), hypertensive controls treated with distilled water (SHR-C; n=10), and SHR treated with imatinib mesylate (Gleevec; Norvatis Pharmaceuticals, Basel, Switzerland) dissolved in distilled water (SHR-I; 30 mg/kg per day; n=10). Treatment with placebo (distilled water) or imatinib was administered orally via gastric gavage starting at 8 weeks and continued until 16 weeks. Rats were caged individually and received normal rat chow and tap water in a temperature-controlled environment under a 12-hour artificial light and dark cycle.
Other experimental protocols are presented in the online-only Data Supplement.
Results
Imatinib Did Not Affect Blood Pressure and Heart Weight in SHR
The body weight of the SHR was significantly lower than that of the WKY control rats, but the blood pressure of the SHR was significantly higher than that of the WKY (Table 1) . Imatinib did not have an effect on the body weight change or systolic blood pressure. Heart weight and heart weight for the tibia length ratio were significantly higher in the SHR group than those in the WKY group. There were no significant differences in heart weight and heart weight/tibia ratio between SHR-C and SHR-I Imatinib Decreased LV Wall Thickness and Improved Diastolic Function in SHR Figure 1 depicts M-mode and Doppler echocardiography of the study subjects. SHR-C showed thicker LV wall, lower E/A ratio, and longer deceleration time than those of WKY (Table 2) . Imatinib was shown to decrease the LV wall thickness and deceleration time and increase the E/A ratio significantly. There was no significant difference in fractional shortening between WKY and SHR-C, and imatinib had no effect on fractional shortening.
Imatinib Decreased LV Hypertrophy and Interstitial Fibrosis in the Hearts of SHR
Heart sections were stained with Masson trichrome and observed under a light microscope. SHR-C displayed LV hypertrophy when compared with WKY, and imatinib attenuated ventricular hypertrophy in SHR rats ( Figure S1 in the online-only Data Supplement). Interstitial and perivascular fibrosis was increased in SHR-C when compared with that in WKY, and it was decreased in SHR-I when compared with that in SHR-C ( Figure 2 ). In addition, quantitative measurements using collagen area fraction demonstrated that imatinib significantly decreased the amount of fibrosis in the interstitial tissue (SHR-C versus SHR-I, 9.8±4.1% versus 1.3±0.2%; P<0.01).
Imatinib Attenuated Myocardial mRNA Expression of Collagen Type I, III, and TGF-β1 in the Hearts of SHR
The myocardial mRNA expressions of collagen type I, III, and TGF-β1 were examined with quantitative reverse transcriptase Doppler echocardiography displayed that early to late diastolic peak velocity (E/A) ratio was reduced in SHR when compared with that in WKY, and this was reversed with imatinib treatment (B). SHR-I indicates spontaneously hypertensive rats treated with imatinib.
polymerase chain reaction. These were significantly increased in SHR when compared with that in WKY and decreased by imatinib treatment (Figure 3 ).
Imatinib Attenuated Myocardial PDGFR Activity in the Hearts of SHR
To access the myocardial phosphorylation state of PDGFR-β, we performed Western blot for the phosphorylated protein on their tyrosine residue and for PDGFR-β in LV. The myocardial phosphorylation of the PDGFR-β was increased in SHR, but it was significantly blunted by imatinib treatment ( Figure 4A and 4B). The total expression of PDGFR-β was also increased in the LV of SHR, and it was significantly decreased by imatinib treatment ( Figure 4A and 4C).
Imatinib Attenuated mRNA Expression of Collagen Type III by Blocking the Phosphorylation of PDGFR-β and c-abl in Rat Cardiac Fibroblasts
Incubation of cultured rat cardiac fibroblast with PDGF-BB increased the phosphorylation of PDGFR-β and mRNA expression of collagen type III. These were decreased by imatinib administration ( Figure 5 ). Incubation of cultured rat cardiac fibroblast with TGF-β1 increased the phosphorylation of c-abl and mRNA expression of collagen type III, and these were also decreased by imatinib administration ( Figure 6 ). In addition, incubation of cultured rat cardial fibroblast with PDGF-BB or TGF-β1 increased the production of collagen III in the culture medium as well, and the administration of imatinib decreased the production of collagen type III ( Figure S2 ).
The Effect of Imatinib on c-abl Phosphorylation in PDGF-BB-Treated Rat Cardiac Fibroblast
Phosphorylation of c-abl was increased when PDGF-BB was added in the rat cardiac fibroblast, and this was attenuated by imatinib administration ( Figure S3 ).
Discussion
This study demonstrated that imatinib mesylate, a tyrosine kinase inhibitor, decreased myocardial fibrosis and resulted in improved LV diastolic dysfunction in a hypertensive rat model. Treatment with 30 mg/kg of imatinib attenuated the accumulation of perivascular and interstitial collagen in the heart. The blunting of collagen synthesis was associated with decreased phosphorylation of PDGFR-β and decreased mRNA expression of TGF-β1. In addition, imatinib attenuated collagen production by inhibiting the phosphorylation of PDGFR-β and c-abl under coincubation with PDGF-BB and TGF-β1, respectively, in cultured rat cardiac fibroblasts. An antifibrotic effect of imatinib has been demonstrated in pulmonary fibrosis, [13] [14] [15] scleroderma fibroblasts, 16, 17 and renal fibroblasts, 18 whereas few studies have investigated the effect of imatinib on the heart. PDGF inhibition by imatinib treatment reduced fibrosis in a rat model of chronic myocarditis and TGR(mRen2) 27 rat, a model of angiotensin II-driven hypertension. 19, 20 However, these previous studies did not show the effect of imatinib on TGF-β1/c-abl pathway, which is another target of imatinib. In chronic hypertension, activated fibroblasts in the connective tissue are responsible for elevated extracellular matrix production, resulting in fibrosis. 21 TGF-β1 and PDGF are key driving forces in fibroblast activation. The best-characterized signaling pathway used by TGF-β1 involves activation of the cellular smad 2/3 pathway. 22 However, recent studies have demonstrated the important roles of non-smad (smad 2/3 independent) signaling pathways in mediating TGF-β1 responses. 18 In the non-smad pathway, c-abl plays a significant role in the regulation of cardiac fibrosis. 23, 24 C-abl is also a novel mediator of TGF-β1-induced fibroblast growth, morphological transformation, and matrix gene expression. 10, 13 PDGF upregulates the expression of TGF-β1 in a rat cardiac allograft 25 and c-abl in fibroblast. 26 In addition, PDGF also directly stimulates fibroblasts to contract collagen matrices and differentiate into myofibroblasts. 10, 18, 19 The strength of our study lies in several points. Our study showed that imatinib effectively inhibited phosphorylation of c-abl and reduced collagen production by blocking TGF-β1/c-abl pathway in rat cardiac fibroblasts. Imatinib also attenuated the phosphorylation of PDGFR and decreased the production of collagen type III in rat cardiac fibroblasts. In addition, TGF-β1/c-abl pathways are affected by PDGF. We observed that c-abl phosphorylation was increased when PDGF-BB was added in the rat cardiac fibroblast, which was attenuated by imatinib administration. Therefore, it can be stated that PDGF promotes fibrosis both on PDGFR and on TGF-β1/c-abl, and imatinib attenuates fibrosis by blocking both pathways. We used SHR as a model for human essential hypertension and observed that imatinib decreased the LV wall thickness and attenuated LV diastolic dysfunction without the blood pressure-lowering effect. This observation substantiates the idea that targeted inhibition of the growth factor system by imatinib may have beneficial effects on cardiac fibrosis and LV remodeling and eventually heart failure. To our knowledge, this is the first study demonstrating the attenuation of myocardial remodeling by imatinib through blocking the phosphorylation of PDGFR-β and inhibiting the TGF-β1 pathways in a hypertensive rat model.
The safety issue related to imatinib use in experimental strategy is still being disputed. Imatinib has been reported to be associated with cardiac toxicity, including congestive heart failure and asymptomatic LV dysfunction in the treatment of patients with chronic myeloid leukemia. In contrast to preclinical findings based on cellular and animal studies, 27 ,28 a long-term follow-up study of patients receiving imatinib for chronic myeloid leukemia did not show any increase in the rates of serious adverse events. 29, 30 There are several potential limitations to our study. First, we did not adopt Tissue Doppler images, a useful technique for evaluating ventricular diastolic function, but we assumed that E/A ratio and deceleration time gave information that proved to be useful in assessing LV diastolic function. Furthermore, we obtained echocardiographic data at similar heart rates to maximize consistency. Second, although we observed reduction in LV wall thickness, heart weight and heart weight/tibia ratio did not differ after imatinib treatment. We speculate that wall thickness is more sensitive than heart weight when assessing LV hypertrophy, and that a sufficient number of animal subjects might have helped to achieve statistical significance on weight changes. Third, we could not demonstrate the effect of imatinib on the phosphorylation of c-abl in our hypertensive rat model (in vivo study, data not shown). We thought that the amount of c-abl proteins might be insufficient in the rat myocardium. In vitro study using rat cardiac fibroblast, however, demonstrated that imatinib blunted the phosphorylation of c-abl, and this was associated with decreased collagen production.
In conclusion, this study is the first one demonstrating that imatinib attenuates myocardial remodeling and improves LV diastolic dysfunction in a hypertensive rat model by blocking the phosphorylation of PDGFR-β and inhibiting the TGF β1 pathway without the blood pressure-lowering effect.
Perspective
This study showed that imatinib reduced cardiac fibrosis, LV wall thickness, and improved LV diastolic dysfunction in a hypertensive rat model. The reduction of collagen production by imatinib was associated with decreased phosphorylation of PDGFR-β and c-abl. These results suggest that imatinib could attenuate myocardial remodeling and improve LV diastolic dysfunction by affecting the action of PDGF and TGF-β1-induced c-abl kinase. Additional work is required to confirm whether imatinib can be a potential therapeutic approach to prevent myocardial fibrosis and diastolic dysfunction in hypertensive heart diseases.
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